Loading clinical trials...

Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms | Clinical Trials | Clareo Health

RECRUITING

Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms

Prospective, Tricentric Open Trial on the Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms

NCT03624712•University Hospital Tuebingen

View on ClinicalTrials.gov

Summary

Evaluation of clinical, therapeutic and prognostic relevance of new experimental results as well as optimization of therapeutic models and development of a new algorithm for therapeutic plan and therapy in patients with uterine neoplasm

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Confirmed uterine malignancy ( cervical cancer, endometrial cancer, sarcoma)
•If operable: surgical primary therapy: laparoscopic/robot-assisted or open radical gyneco-oncological surgery
•Written consent
•Willingness and ability to participate in all study-specific procedures
•Age ≥ 18 years

Exclusion Criteria

•Severe and acute general disease in the last 4 weeks
•Acute or chronic psychiatric disorders
•Other factors questioning study participation (e.g. acute psychosocial stress, insufficient understanding of nature and consequences of the study, inadequate skills of the German language)

Locations (1)

University Hospital Tuebingen, Department of Women's Health

Tübingen, Germany

Key Dates

Start Date

January 1, 2012

Primary Completion Date

December 1, 2027

Completion Date

December 1, 2027

Last Updated

January 17, 2025

Enrollment

580

ESTIMATED participants

Conditions

Uterine Neoplasms

Interventions

uterine neoplasms

DIAGNOSTIC_TEST

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369

Advanced Solid TumorsBreast Cancer+25 more

View study

ACTIVE_NOT_RECRUITINGPHASE2

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380

Uterine NeoplasmsUterine Cervical Neoplasms+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms

Inclusion Criteria

Exclusion Criteria

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer

An In-vitro Real-time System Based on Tissue Smears to Identify Malignancy During Hysteroscopic Procedure